Navigation Links
Continuous-Elution Electrophoresis for Purification of the Baculovirus-Expressed Coronavirus Structural Proteins, Rev A

K. Sestak, L. Kim, K.-O. Chang and L. J. Saif, Food Animal Health Research Program, Ohio Agricultural Research and Development Program, The Ohio State University, Wooster, OH 44691

Three major structural proteins of the porcine coronavirus, transmissible gastroenteritis virus (TGEV), membrane (M), nucleocapsid (N), and spike (S), were expressed in a baculovirus expression system. A method for rapid purification of the virus-specific proteins from cellular components was developed by using continuous-elution polyacrylamide gel electrophoresis (CE-PAGE). This approach might be a valuable preparative tool prior to immunization studies, monoclonal antibody production, subunit vaccine preparation, quantification of protein expression and for other experimental scenarios where purified viral proteins are required.


TGEV causes diarrhea and vomiting in pigs of all ages and produces 90100% mortality in 12 week old sero-negative pigs (Bohl et al., 1972). The economic impact of TGEV on the U.S. pork industry was estimated as $200 million per year (Saif and Wesley, 1992). A possible vaccine includes the three purified recombinant TGEV structural proteins embedded in immuno-stimulating complexes (ISCOMs), microcapsules or other carriers.

Materials and Methods

The Sf9 insect cells containing the TGEV proteins were harvested from 150 cm2 stationary cell culture flasks (1.8 x 107 cells) and resuspended in 1 ml of phosphate buffer saline (PBS), pH 7.3, mixed with 4 parts of sample buffer (0.06 M Tris, pH 6.8; 10% glycerol; 2% (w/v) SDS; 5% mercaptoethanol and 0.05% (w/v) bromophenol blue), heated at 95 C for 4 min and stored at 20 C until used for preparative electrophoresis.

A Mini Prep Cell (Bio-Rad Laboratories, Hercules, CA) system was used to perform continuous-elution polyacrylamide gel electrophoresis (CE-PAGE) with conditions modified for each TGEV protein to be purified. For the TGEV M-protein, the sample (0.5 ml, corresponding to 18 x 105 cells) was layered onto a 4% (1.5 cm) polyacrylamide stacking gel with a 10% (8 cm) polyacrylamide separating gel. Proteins were electrophoresed under denaturing conditions at constant voltage (200 V) for 3.5 h with a flow rate of 0.05 ml/min. After 3.5 h, fractions were collected in 5 min intervals (0.25 ml/fraction) with a total of 30 fractions. For the TGEV N-protein electrophoresis was performed as described above, but for 4.5 h prior to collection of 30 fractions. For the TGEV S-protein; the sample (0.5 ml, corresponding to 18 x 105 cells) was layered onto a 4% (1.5 cm) polyacrylamide stacking gel with a 6% (8 cm) polyacrylamide separating gel in the Mini Prep Cell gel tube assembly. Electrophoresis was performed as described above for 8.5 h prior to collection of the 30 fractions.

Selected protein fractions were examined by electrophoresis in analytical polyacrylamide slab gels and stained with Coomassie blue (Wu and Welsh, 1996). The fractions of desired molecular weight were pooled and concentrated using Centricon devices (Amicon, Beverly, MA) with a 10 kDa cutoff for the M-protein, and a 30 kDa cutoff for the N- and S-proteins. Virus specificity of the M-, N-, and S-proteins and conformational stability of the N-protein and epitopes A and D of the S-protein were confirmed by immunoblo tting using porcine hyperimmune antiserum to TGEV (Stott, 1989) or a TGEV neutralizing monoclonal antibody specific for epitope A of the S-protein (25C9) and non-neutralizing monoclonal antibodies specific for epitope D of the S-protein (44C11) and N-protein (25H7) (Lanza et al., 1995). The protein concentration was estimated with spectrophotometer readings at 280 nm.

By extrapolating the molecular size to prestained protein standards or to native coronavirus proteins from virus (Wesley et al., 1991) cell culture adapted TGEV (Miller strain), the recombinant TGEV M-protein (2831 kDa) was expected to be eluted within fraction range 913 (Figure 1A). Fractions 913 were pooled and concentrated. The presumed M-protein was electrophoresed and detected by Coomassie blue stain (Figure 1B, lane 5) and its virus specificity was confirmed by western blot (Figure 1C, lane 5). After concentration of fractions 913, the final protein concentration was 0.4 mg/ml or 5% of the initial solubilized cell lysate protein.

The recombinant TGEV N-protein (47 kDa) was expected to be within fraction range 2527 (Figure 2A). These fractions were pooled and concentrated. The concentrated sample was analyzed as described for the recombinant TGEV M-protein (Figure 2B, C). The resulting purified N-protein concentration was 0.5 mg/ml, or 8% of the initial baculovirus lysate.

The recombinant TGEV S-protein (150 kDa) was expected to be within fraction range 2030 (Figure 3A). Fractions 2030 were pooled and concentrated. The concentrated S-protein sample was further analyzed as described for the M- and N-proteins (Figure 3B, C). In addition to the major band of 150 kDa, a minor, virus-specific band of 100 kDa was detected on both polyacrylamide gels and nitrocellulose membranes (Figure 3B, C, lane 5). The resulting purified S-protein concentration was 0.15 mg/ml or 2% of the initial baculovirus lysate.


The production of subunit viral vaccines requires the purification of the immunogens of interest from other cellular proteins. The CE-PAGE represents an approach whereby proteins are electrophoretically separated based on their molecular size and collected in fractions.

The yields of purified M-, N- and S-proteins corresponding to the 18 x 105 Sf9 insect cells (0.5, 0.4 and 0.15 mg/ml, respectively) are reflective of the levels of recombinant protein expected (28%) and in agreement with data published on the efficiency of the baculovirus expression system (Luckow et al., 1988). Elution of small volumes of purified, concentrated proteins (0.20.5 ml) reflects the capacity of the Mini Prep Cell system, but can be scaled up when larger amounts are required by using the same conditions and a Model 491 Prep Cell.

By western blotting of the purified proteins with porcine hyperimmune antiserum to TGEV (S, M, N) in western blot and the ELISA reaction with monoclonal antibodies (S, N), we demonstrated that immunogenic and neutralizing epitopes were preserved on the purified proteins. On both polyacrylamide gels and nitrocellulose membranes, a minor 100 kDa protein band in addition to the major 150 kDa protein was detected for the TGEV-S protein (Figure 3B, C, lane 5). This most likely reflected the presence of an immature, posttranslationally non-modified form of S-glycoprotein as previously reporte d (Shoup et al., 1997) or cleavage product. Similarly, a minor protein band in addition to the full size recombinant TGEV-M protein was detected by western blot (Figure 1C, lanes 3 and 5).

The results from this study suggest that CE-PAGE can be a useful semi-preparative tool to purify baculovirus-expressed TGEV viral proteins.


The authors thank Drs. H. Laude, D. J. Jackwood and D. I. Shoup for providing the recombinant baculovirus plasmid (N) or constructs (S, M).


1. Bohl, E. H., et al., Antibody responses in serum, colostrum and milk of swine after infection or vaccination with transmissible gastroenteritis virus, Infect. Immun., 6, 289301 (1972).

2. Lanza, I., et al., Lactogenic immunity and milk antibody isotypes to transmissible gastroenteritis virus in sows exposed to porcine respiratory coronavirus during pregnancy, Am. J. Vet. Res., 56, 739748 (1995).

3. Luckow, V. A. and Summers, M. D., Trends in the development of baculovirus expression vectors, Biotechnol., 6, 4755 (1988).

4. Saif, L. J. and Wesley, R. D., Transmissible gastroenteritis. In: Leman, A.D., et al., (Eds), Diseases of Swine. 7th edn., Iowa State University Press, Ames, pp. 362386 (1992).

5. Shoup, D. I., et al., Active and passive immune responses to transmissible gastroenteritis virus (TGEV) in swine inoculated with recombinant baculovirus-expressed TGEV spike glycoprotein vaccines, Am. J. Vet. Res., 58, 242250 (1997).

6. Stott, D. I., Immunoblotting and dot blotting, J. Immunol. Methods, 119 , 153187 (1989).

7. Wesley, R. D., et al., Differentiation between transmissible gastroenteritis virus and porcine respiratory coronavirus using a cDNA probe, J. Vet. Diagn. Invest., 3, 2932 (1991).

8. Wu, W. and Welsh, M. J., Rapid Coomassie blue staining and destaining of polyacrylamide gels, Biotechniques, 20, 386388 (1996).

Coomassie is a trademark of ICI.

back to top


Page: All 1 2 3 4 5 6

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. A Multiple Mutation Model System as a Test Development and Training Tool for Denaturing Gradient Gel Electrophoresis
3. Detection of K-ras Point Mutations in the Pancreas by Constant Denaturing Gel Electrophoresis Using the DCode System
4. Detection of Mutations in the Fas Antigen of Lymphoma Tumors by RT-PCR and Denaturing Gradient Gel Electrophoresis
5. Detection of Variation in Highly Polymorphic Mhc Genes by Denaturing Gradient Gel Electrophoresis Using the DCode System
6. Detection of p53 Gene in Breast Cancer by Denaturing Gradient Gel Electrophoresis and the DCode System
7. Identification of Disease Causing Mutations in Phenylketonuria by Denaturing Gradient Gel Electrophoresis Using the DCode System
8. Microbial Diversity in Ground and Surface Water Analyzed by Denaturing Gradient Gel Electrophoresis Using the DCode System
9. Oligonucleotide Purity Analysis by Capillary Electrophoresis
10. Preparative Nondenaturing Gel Electrophoresis Used in the Purification of an Esterase Involved in Insecticide Resistance, Rev C
11. Preparative Nondenaturing Gel Electrophoresis to Purify NADP-Specific Glutamate Dehydrogenase From Chlorella, Rev B
Post Your Comments:

(Date:2/22/2017)... , Feb 22, 2017 Dublin ... the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By Application, ... report to their offering. ... Global Biological Crop Protection Market is forecasted to ... The strong growth in biopesticide or biological crop protection market is ...
(Date:2/22/2017)... Aethlon Medical, Inc. (Nasdaq: AEMD ... validated the ability of the Aethlon Hemopurifier® to capture ... in immune-suppressed sepsis patients and also contribute to organ ... of the study was to validate the in ... and Herpes Simplex virus 1 (HSV1) by the Hemopurifier®. ...
(Date:2/22/2017)... Zurich, Switzerland (PRWEB) , ... February 22, 2017 ... ... Ltd ., announced the addition of Tom Perkins as European director. Operating from ... consulting experience to Pennside. , Perkins joins Pennside after more than a ...
(Date:2/22/2017)... N.C., Feb. 22, 2017  United Therapeutics Corporation (NASDAQ: ... results for the fourth quarter and year ended ... results reflect continued growth as net revenues reached ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and Chief ... to develop and advance our growing product pipeline, ...
Breaking Biology Technology:
(Date:2/7/2017)... York , February 7, 2017 ... ID Global Solutions Corporation [OTC: IDGS], ("Ipsidy" or the ... and electronic transaction processing services, is pleased to announce ... the Company. Effective January 31, 2017, ... Board of Directors, CEO and President.  An experienced payment ...
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/31/2017)... , Jan. 31, 2017  Spero Therapeutics, ... therapies for the treatment of bacterial infections, today ... of antibacterial candidates from Pro Bono Bio Ltd ... prevalence of multi-drug resistant forms of Gram-negative bacteria.  ... Anti Infectives Ltd, a PBB group company. ...
Breaking Biology News(10 mins):